IS ASIA READY FOR BIOSIMILARS? A REVIEW OF THE REGULATORY LANDSCAPE FOR BIOSIMILARS?

被引：0
|
作者：
Duttagupta, S. [1 ]
Park, S. [1 ]
Akandwanaho, D. [1 ]
Jeong, J. J. [1 ]
Feldman, H. [1 ]
机构：
[1] CBPartners, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.430
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP97
引用
收藏
页码：S56 / S57
页数：2
相关论文
共 50 条
  • [41] Biosimilars: State of Clinical and Regulatory Science
    Klein, Agnes V.
    Wang, Jian
    Feagan, Brian G.
    Omoto, Mark
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2017, 20 : 332 - 348
  • [42] Strengths and weaknesses of the Brazilian regulation on biosimilars: A critical view of the regulatory requirements for biosimilars in Brazil
    de Assis, Marcos Renato
    Pinto, Valdair
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2018, 10 (12) : 253 - 259
  • [43] Biosimilars: Current Scientific and Regulatory Considerations
    Chugh, Preeta Kaur
    Roy, Vandana
    CURRENT CLINICAL PHARMACOLOGY, 2014, 9 (01): : 53 - 63
  • [44] Biosimilars: the impact of their heterogeneity on regulatory approval
    Asterios S Tsiftsoglou
    Nature Reviews Drug Discovery, 2007, 6 (3) : 252 - 252
  • [45] Biosimilars: a regulatory perspective from America
    Jonathan Kay
    Arthritis Research & Therapy, 13
  • [46] A review of biosimilars for rheumatoid arthritis
    Conran, Carly A.
    Moreland, Larry W.
    CURRENT OPINION IN PHARMACOLOGY, 2022, 64
  • [47] Regulatory aspects of biosimilars: Myths and facts [Regulatorische Aspekte zu Biosimilars: Mythen und Fakten]
    Schneider C.K.
    Weise M.
    Zeitschrift für Rheumatologie, 2015, 74 (8) : 695 - 700
  • [48] The regulatory landscape of biosimilars: Algeria's efforts and progress made from 2006 to 2021
    Benahzil, M. A.
    Hadjaz, I. M.
    Mansouri, K.
    ANNALES PHARMACEUTIQUES FRANCAISES, 2022, 80 (04): : 440 - 447
  • [49] Biosimilars and implications for pharmacy practice: Ready or not, here they come!
    Hobbs, Andrea L.
    Crawford, Joshua P.
    PHARMACY PRACTICE-GRANADA, 2019, 17 (03):
  • [50] Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo, Marjorie
    Fiorino, Gionata
    Gilardi, Daniela
    Furfaro, Federica
    Roda, Giulia
    Loy, Laura
    Allocca, Mariangela
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (01) : 7 - 12
12345